Hyperthermia
News
On 14 June 2024, our industry symposium entitled “Quality-assured Hyperthermia and Flash Radiotherapy” took place as part of the 30th Congress of the German Society for Radiation Oncology (DEGRO). Prof Dr Udo Gaipl (Head of Translational Radiobiology, Radiation Immunobiology, Department of Radiation Oncology, University Hospital Erlangen) and PD Dr med. habil. Gunther Klautke (Congress President DEGRO, Director of the Clinic of Radiation Oncology, Chemnitz Hospital) assumed the role of chairmen.
The lecture “Do the immunological Effects of Hyperthermia and FLASH Radiotherapy go together?” by Prof. Dr Udo Gaipl is now available for download as a PDF.
View the detailed presentation in its entirety (PDF)
Events
All Events- 28th Annual SASRO Meeting 2024 – Scientific Association of Swiss Radiation Oncology Sursee/Luzern, Switzerland Sep. 19 – 21, 2024
- 54th Hyperthermietreffen Atzelsberger Kreis Erlangen, Germany Sep. 26 – 27, 2024
- neurorad - 59th Annual Conference of the German Society of Neuroradiology Kassel, Germany Oct. 09 – 11, 2024
- 41st ÖGRO Jahrestagung 2024 – Österreichische Gesellschaft für Radioonkologie, Radiobiologie und Medizinische Radiophysik Graz, Austria Oct. 18 – 19, 2024
- ESHO 2024 – 36th Annual Meeting of the European Society for Hyperthermic Oncology Malaga, Spain Nov. 06 – 08, 2024
Publication in EJC
The HEAT Trial
Pancreatic cancer: Hyperthermia trial demonstrates significantly improved post-recurrence survival
The randomized clinical trial "Hyperthermia European Adjuvant Trial" (HEAT) investigated regional hyperthermia (RHT) with cisplatin added to gemcitabine compared to chemotherapy with gemcitabine alone in the adjuvant treatment after resection of pancreatic cancer. The results show a significantly improved post-recurrence survival and a trend towards improved overall survival using Pyrexar Medical's BSD-2000 3D radiative hyperthermia system. Pancreatic cancer is one of the most common causes of cancer-related death worldwide. The HEAT trial was prematurely stopped in May 2018, when the modified FOLFIRINOX regimen replaced gemcitabine as standard therapy. The trial included a total of 117 patients with a median follow-up of 56.6 months.
Hyperthermia
Technology
Paul Turner, CTO at Pyrexar Medical Corporation covers “Present and Future Hyperthermia Technology Evolution”.
Paul Turner has been developing hyperthermia and ablation heat treatment methods for more than 40 years, including RF phased array systems for deep non-invasive and invasive phased arrays.
